Abstract
Experience during the past 10 years has shown up different opinions on the surgical treatment of patients with stage III non-small cell lung cancer. In the light of high resectability and survival rates (respectively 80.8% and 40% at 2 years in the experience of the Southwest Oncology Group) produced with neoadjuvant therapy (followed by surgery) it appears to be an appealing therapeutic option. Until recently, there have been no large prospective randomized phase III trials to answer the question of whether neoadjuvant therapy is superior to other treatment modalities (surgical resection alone; non-surgical treatment).
| Original language | Italian |
|---|---|
| Pages (from-to) | 30-33 |
| Number of pages | 4 |
| Journal | Chirurgia Italiana |
| Volume | 47 |
| Issue number | 3 |
| Publication status | Published - 1995 |
Fingerprint
ASJC Scopus subject areas
- Surgery
Cite this
La terapia chirurgica del carcinoma del polmone non-microcitoma localmente avanzato. / Martelli, M.; Cardillo, G.; Lopergolo, M.; Facciolo, F.
In: Chirurgia Italiana, Vol. 47, No. 3, 1995, p. 30-33.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - La terapia chirurgica del carcinoma del polmone non-microcitoma localmente avanzato.
AU - Martelli, M.
AU - Cardillo, G.
AU - Lopergolo, M.
AU - Facciolo, F.
PY - 1995
Y1 - 1995
N2 - Experience during the past 10 years has shown up different opinions on the surgical treatment of patients with stage III non-small cell lung cancer. In the light of high resectability and survival rates (respectively 80.8% and 40% at 2 years in the experience of the Southwest Oncology Group) produced with neoadjuvant therapy (followed by surgery) it appears to be an appealing therapeutic option. Until recently, there have been no large prospective randomized phase III trials to answer the question of whether neoadjuvant therapy is superior to other treatment modalities (surgical resection alone; non-surgical treatment).
AB - Experience during the past 10 years has shown up different opinions on the surgical treatment of patients with stage III non-small cell lung cancer. In the light of high resectability and survival rates (respectively 80.8% and 40% at 2 years in the experience of the Southwest Oncology Group) produced with neoadjuvant therapy (followed by surgery) it appears to be an appealing therapeutic option. Until recently, there have been no large prospective randomized phase III trials to answer the question of whether neoadjuvant therapy is superior to other treatment modalities (surgical resection alone; non-surgical treatment).
UR - http://www.scopus.com/inward/record.url?scp=0029434575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029434575&partnerID=8YFLogxK
M3 - Articolo
C2 - 8964096
AN - SCOPUS:0029434575
VL - 47
SP - 30
EP - 33
JO - Chirurgia Italiana
JF - Chirurgia Italiana
SN - 0009-4773
IS - 3
ER -